In leukemia and lymphoma, CD137 expression could promote the growth and survival of malignant cells and inhibit T cell activation [7, 8], suggesting that the overall effect of CD137 expression in cancer cells might be immunosuppressive. This evidence concerns the gene TNFRSF9 and lymphoma.